Abstract
Membrane fusion is an essential step in the entry of enveloped viruses into their host cells, what makes it a potentially attractive target for viral inactivation approaches. Fusion is mediated by viral surface glycoproteins that undergo conformational changes triggered by interaction with specific cellular receptors or by the exposition to low pH of endossomal medium. Here we review how several studies on the structural rearrangements of vesicular stomatitis virus (VSV) glycoprotein G during cellular recognition and fusion led us to propose a crucial role of the protonation of His residues for G protein activity. Moreover, we demonstrated that using diethylpyrocarbonate (DEPC), a histidine-modifying compound, it was possible to abolish viral infectivity and pathogenicity in mice, and to elicit neutralizing antibodies that confer protection in these animals against challenge using lethal doses of the virus. The presence of conserved His residues in a wide range of viral fusion proteins and the use of DEPC as a more general means for vaccine development will be also discussed.
Keywords: Membrane fusion, viral inactivation, histidine protonation, vesicular stomatitis virus, diethylpyrocarbonate
Protein & Peptide Letters
Title: Viral Inactivation Based on Inhibition of Membrane Fusion: Understanding the Role of Histidine Protonation to Develop New Viral Vaccines
Volume: 16 Issue: 7
Author(s): A.T. Da Poian, F. A. Carneiro and F. Stauffer
Affiliation:
Keywords: Membrane fusion, viral inactivation, histidine protonation, vesicular stomatitis virus, diethylpyrocarbonate
Abstract: Membrane fusion is an essential step in the entry of enveloped viruses into their host cells, what makes it a potentially attractive target for viral inactivation approaches. Fusion is mediated by viral surface glycoproteins that undergo conformational changes triggered by interaction with specific cellular receptors or by the exposition to low pH of endossomal medium. Here we review how several studies on the structural rearrangements of vesicular stomatitis virus (VSV) glycoprotein G during cellular recognition and fusion led us to propose a crucial role of the protonation of His residues for G protein activity. Moreover, we demonstrated that using diethylpyrocarbonate (DEPC), a histidine-modifying compound, it was possible to abolish viral infectivity and pathogenicity in mice, and to elicit neutralizing antibodies that confer protection in these animals against challenge using lethal doses of the virus. The presence of conserved His residues in a wide range of viral fusion proteins and the use of DEPC as a more general means for vaccine development will be also discussed.
Export Options
About this article
Cite this article as:
Da Poian A.T., Carneiro A. F. and Stauffer F., Viral Inactivation Based on Inhibition of Membrane Fusion: Understanding the Role of Histidine Protonation to Develop New Viral Vaccines, Protein & Peptide Letters 2009; 16 (7) . https://dx.doi.org/10.2174/092986609788681823
DOI https://dx.doi.org/10.2174/092986609788681823 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Treatment of Viral Encephalitis
Central Nervous System Agents in Medicinal Chemistry The Role of Immune System in Schizophrenia
Current Immunology Reviews (Discontinued) In Vitro Evidence for Competitive TSPO Binding of the Imaging Biomarker Candidates Vinpocetine and Two Iodinated DAA1106 Analogues in Post Mortem Autoradiography Experiments on Whole Hemisphere Human Brain Slices
Current Radiopharmaceuticals Editorial [Hot Topic: Protein Peptide Informatics and Drug Designing - Some Computational Techniques for Structural Genomics Based Approaches (Part II) (Guest Editor: Rajani R. Joshi)]
Protein & Peptide Letters Biological Activities of Yarrow Species (Achillea spp.)
Current Pharmaceutical Design VEGF in Tumor Progression and Targeted Therapy
Current Cancer Drug Targets Neurological Effects of SARS-CoV-2 and Neurotoxicity of Antiviral Drugs Against COVID-19
Mini-Reviews in Medicinal Chemistry Heme Oxygenase-1 Dysregulation in the Brain: Implications for HIVAssociated Neurocognitive Disorders
Current HIV Research Neuroprotective Effects of Tetracyclines: Molecular Targets, Animal Models and Human Disease
CNS & Neurological Disorders - Drug Targets Reading and Writing the Blood-Brain Barrier: Relevance to Therapeutics
Recent Patents on CNS Drug Discovery (Discontinued) Recent Advances in Targeting Viral Proteases for the Discovery of Novel Antivirals
Current Topics in Medicinal Chemistry Oseltamivir in Neonates, Infants and Young Children: A Focus on Clinical Pharmacology
Infectious Disorders - Drug Targets Nanoparticle- and Liposome-carried Drugs: New Strategies for Active Targeting and Drug Delivery Across Blood-brain Barrier
Current Drug Metabolism Pathogenesis of Central Nervous System Tuberculosis
Current Molecular Medicine PI3K-Akt Signaling and Viral Infection
Recent Patents on Biotechnology Non-IgE Mediated Food Allergy – Update of Recent Progress in Mucosal Immunity
Inflammation & Allergy - Drug Targets (Discontinued) An Ion Channel Chip for Diagnosis and Prognosis of Autoimmune Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Autoimmune Channelopathies of the Nervous System
Current Neuropharmacology Burkholderia mallei and Burkholderia pseudomallei: The Causative Micro-organisms of Glanders and Melioidosis
Recent Patents on Anti-Infective Drug Discovery